Data from Eli Lilly and Company’s Humulin® R U-500 administered via an investigational insulin pump was presented at the American Diabetes Association (ADA) 78th Scientific Sessions® in Orlando. The Omnipod® U-500™ Insulin Management System provided greater A1C reduction with less daily insulin needed compared to multiple daily injections (MDI) in adults with type 2 diabetes on high dose insulin (201-600 units/day).
Humulin R U-500 is Lilly’s highly concentrated insulin formulation that is used to control high blood sugar in people with diabetes who are insulin-resistant and need daily doses of more than 200 units of insulin.
At the study’s primary endpoint of 26 weeks, Humulin R U-500 delivered in the investigational pump and through MDI led to A1C reductions from baseline in people with type 2 diabetes. Beginning at week eight through the duration of the study, A1C improvement was greater with the pump compared to MDI. Humulin R U-500 delivered in a pump also led to lower total daily insulin dose compared to MDI (difference of -0.47 units/kg at the primary endpoint).
There was no significant difference in documented symptomatic or severe hypoglycemia between the pump and MDI. Nocturnal hypoglycemia was higher with the pump compared to MDI.
Tom Hardy, senior medical director at Lilly said, “People who prefer to use an insulin pump currently do not have an option specifically for Humulin R U-500, which is five-times concentrated. These data show that Humulin R U-500 delivered with this investigational pump may help people better manage their blood sugar levels.”
Dr. Trang Ly, senior vice president and medical director, Insulet Corporation said, “These results show that Humulin R U-500 using Insulet Corporation’s Omnipod technology may help make it easier for people to titrate to their individual needs and improve their blood glucose control.”